| Organizer |
Oct.14(Wed.) 10 : 00 ~ 11 : 30 |
F203-206 |
|---|
| 【K-1】 Keynote Lecture |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
Keynote Lecture
|
|
Shigeru Omi President of JAPAN Community Health care Organization (JCHO) 
Translating IL-6 biology into effective treatment Prof. Tadamitsu Kishimoto Specially Appointed Professor
In Japanese
Japan's Bioeconomy Strategy 2020 Osamu Nagayama President, Japan Bioindustry Association 
|
| Sponsor |
Oct.14(Wed.) 12 : 00 ~ 13 : 00 |
|---|
| 【S-2】 LEO Pharma K. K. |
|---|
|
Pre-Registration required Online Seminar
Dreaming the future of life sciences through the alliance of LEO Pharma, CIC Tokyo and Venture Cafe TokyoLEO Pharma is a Denmark-based pharmaceutical company with strengths in the field of dermatological diseases. CIC Tokyo opened up the largest innovation hub in Tokyo in October. Venture Cafe Tokyo has established a huge network of innovators in 12 locations around the world. The borderless alliance of these three parties aims at fostering a startup ecosystem and building a strategy for innovation and serendipity based on their know-how, space and network. Please watch our session and join our powerful network! |
|
LEO Science & Tech Hub - Better tomorrow for patients with skin diseases through cutting-edge science & technologies Dr. Taruho KURODA Director
In Japanese
CIC Tokyo - The birth of globally connected innovation hub in Tokyo Prof. Takaaki UMEZAWA Chairman
In Japanese
Venture Cafe Tokyo - Connecting people to make things happen in life science industry Prof. Yasuhiro YAMAKAWA Executive director
In Japanese
PANEL DISCUSSION Joint session by LEO Pharma, CIC Tokyo & Venture Cafe Tokyo - Towards Creation of a Startup Ecosystem【English session with Japanese subtitle】 Dr. Tord LABUDA Vice President
In Japanese
Prof. Takaaki UMEZAWA Chairman
In Japanese
Prof. Yasuhiro YAMAKAWA Executive Director
In Japanese
Dr. Taruho KURODA (Moderator) Director
In Japanese
|
| Organizer |
Oct.14(Wed.) 13 : 00 ~ 14 : 30 |
F203-204 |
|---|
| 【O-3】 COVID-19: Forefront of Diagnosis (tentative) |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
COVID-19: Forefront of Diagnosis (tentative)
Coordinator Prof. Tatsuhiko Kodama Research Center for Advanced Science and Technology, The University of Tokyo 
|
|
Antibody Testing for SARS-CoV-2(COVID-19) and Infection Control Prof. Kawamura Takeshi Associate Professor
In Japanese
Laboratory diagnosis methods for COVID-19 Prof. Kimura Hirokazu Professor
In Japanese
Contribution of human host genomics to prevention of COVID-19 pandemic Prof. Yukinori Okada Professor 
|
| Sponsor |
Oct.14(Wed.) 13 : 30 ~ 14 : 30 |
F201-202 |
|---|
| 【S-1】 Noster Inc. |
|---|
|
Pre-Registration required Simultaneous interpretation
Creating innovative therapeutic agents by controlling the gut microbiome
Dysbiosis is frequently reported to be associated with illnesses such as inflammatory bowel disease (IBD), obesity, cancer, etc. Immunoglobulin A (IgA) is the antibody secreted into the intestinal lumen. IgA plays a critical role in the defense against pathogens and in the maintenance of intestinal homeostasis through gut microbial control. However, how secreted IgA regulates gut microbiota is not completely understood. Our main question is what kind of bacterial molecule an intestinal high-affinity IgA recognizes and targets. To address this question, we generated hybridomas from IgA producing cells in small intestine of wild type mice. As a candidate of efficient gut microbiota modulator, we selected a W27 IgA. W27 IgA selectively inhibited the in vitro growth of bound bacteria, including Escherichia coli (E. coli), suggesting that W27 IgA has an ability to improve the intestinal environment. Thus, W27 IgA oral treatment is a potential remedy for a variety of diseases associated with dysbiosis, acting through restoration of the host-microbial symbiosis. |
|
Gut microbial metabolites (postbiotics) as an alternative state dual controller that simultaneously controls disease state and intestinal flora Prof. Jun Ogawa Professor
In Japanese
Intestinal IgA as a gut microbial modulator Prof. Reiko Shinkura Professor
In Japanese
Noster company’s information Dr. Yasunori Yonejima Research Manager
In Japanese
|
| Sponsor |
Oct.14(Wed.) 14 : 00 ~ 15 : 30 |
G303-304 |
|---|
| 【S-3】 Manufacturing Technology Association of Biologics |
|---|
|
Pre-Registration required
Manufacturing Technology Association of BiologicsThe Manufacturing Technology Association of Biologics (MAB) developed integrated technology platforms for the biologics production. Technology Association is non-profit mutual benefit organization (cooperation) and this association focused on manufacturing of biologics including therapeutic antibody, recombinant protein, and gene therapy. In this presentation, we will introduce the research and developments (5 young researchers: Dr. Yamano-Adachi, Dr. Onitsuka, Dr.Kawabe, Dr.Yoshimoto, Dr. Sugiyama and 7 organizations: Chitose Laboratory Corp., Able Corporation, Fujimori Kogyo Co.,Ltd., Fuji Film Wako Pure Chemical Corporation, YMC Co.,Ltd., National Institute of Advanced Industrial Science and Technology / MAB, Sumitomo Bakelite Co.,Ltd.) under AMED (Japan Agency for Medical Research and Development) project in manufacturing technologies for therapeutic protein and gene therapy and discuss about next-generation manufacturing platform in biologics production. |
|
Next-generation platform manufacturing～From therapeutic antibody to cell and gene therapy Dr. Omasa Takeshi Manufacturing Technology Association of Biologics Project Leader／ Graduate School of Engineering, Osaka University Professor／ Tokushima University Visiting Professor／ Kobe University Visiting Professor
In Japanese
|
| Organizer |
Oct.14(Wed.) 15 : 00 ~ 17 : 00 |
F203-204 |
|---|
| 【O-5】 Emergency Discussion: Current Situation of COVID-19 Vaccination (tentative) |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
Emergency Discussion: Current Situation of COVID-19 Vaccination (tentative)
Coordinator Dr. Yoshihiro Kawaoka professor |
|
Activity by Japanese Regulatory Authorities to Evaluate the Efficacy and Safety of COVID-19 Vaccines Mr. Yasuhiro Araki Director
In Japanese
Development of DNA Vaccine Against Novel Corona Virus Prof. RYUICHI MORISHITA Professor
In Japanese
Vaccine development for COVID-19 Dr. Fumihiko TAKESHITA Vice President
In Japanese
Development of an Inactivated Vaccine for COVID-19 Dr. Kengo Sonoda General Manager
In Japanese
Development of Recombinant Protein Vaccine for COVID-19 Dr. Ryuichi Kiyama Senior Executive Officer, Senior Vice President
In Japanese
【Recorded Presentation】 Dr. Hanneke Schuitemaker Dr. Tadahiro Fujino Head of Clinical Science, R&D 
|
| Organizer |
Oct.15(Thu.) 10 : 00 ~ 11 : 30 |
F203-204 |
|---|
| 【O-7】 COVID-19: Forefront of Treatment (tentative) |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
COVID-19: Forefront of Treatment (tentative)
At present, our knowledge of the treatment of COVID-19 with antiviral drugs is limited. Remdesivir is an RNA-dependent RNA polymerase inhibitor that has shown widespread activity against RNA viruses. It was approved for use in Japan on May 7, 2020, under a special approval system. Coordinator Dr. Ohmagari Norio Director 
|
|
AMED’s role for R&D related to combating the novel coronavirus Disease (COVID-19) Mr. Katsufumi JO Executive Director
In Japanese
Remdesivir: the first approved treatment for SARS-CoV-2 infection in Japan Dr. Masayuki Omote Executive Director, Clinical Research
In Japanese
Anti-IL-6 receptor antibody Actemra for the treatment of patients with severe COVID-19 pneumonia Dr. Minoru Watanabe Vice President, Head of Project & Lifecylcle Management Unit
In Japanese
|
| Sponsor |
Oct.15(Thu.) 13 : 30 ~ 14 : 30 |
F201-202 |
|---|
| 【S-5】 Patheon by Thermo Fisher Scientific |
|---|
|
Pre-Registration required
Patheon CDMO services updates
|
|
Mr. Koji Tanimoto Business Development Director, Asia Pacific
In Japanese
Patheon™ Viral Vector Services Mr. Patrick Robertson Director, Techinical Sales Operations 
Leveraging innovative technologies, best practices and strategies to accelerate biologics development and commercialization Prof. Jeff Hou Thermo Fisher Scientific, Pharma Services 
|
| Organizer |
Oct.15(Thu.) 13 : 30 ~ 15 : 00 |
F203-204 |
|---|
| 【O-11】 How does artificial intelligence change the medical and pharmaceutical industries? |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
How does artificial intelligence change the medical and pharmaceutical industries?
|
|
Re-energising Small Molecule Drug Discovery by AI: From Discovery Concept to Clinical Candidate Dr. Daisuke Tanaka Representative Director
In Japanese
Utilizaton of AI in the field of health, labour and welfare Mr. Shinichi TAKAE Director for Research Planning
In Japanese
【Recorded Presentation】 Dr. Jason LaBonte |
| Organizer |
Oct.15(Thu.) 15 : 00 ~ 16 : 30 |
G301-302 |
|---|
| 【O-14】 [Forefront of biopharmaceutical production] Is there enough human resources for development and manufacturing of biologics in your organization? ~ Under the situation that modalities of biopharmaceuticals are diversifying~ |
|---|
|
Pre-Registration required
【Forefront of biopharmaceutical production 】Is there enough human resources for development and manufacturing of biologics in your organization? ~ Under the situation that modalities of biopharmaceuticals are diversifying～It has been pointed out that technological development and human resource development for biopharmaceutical manufacturing are important even in Japan under the situation that modalities of biologics are diversifying. From the same perspective, the importance of human resource development can be seen in the policy recommendations of the Japan Pharmaceutical Manufacturers Association Biopharmaceutical Committee. In this session, we will review the direction of next-generation manufacturing technological innovation in response to the diversification of modalities and the utilization of digital technology for bioproduction, and clarify the human resources image required for biopharmaceutical manufacturing in the future. Coordinator Prof. Uchida kazuhisa Kobe University 
|
|
Needs for human resources to develop and manufacture biopharmaceuticals and regenerative medicine -from survey results for companies Mr. Yoshihiro Watanabe Chairperson of Subcommittee on Policy Issues
In Japanese
Training for research and development of biologics in Biologics Center for Research and Training (BCRET) Dr. Satoshi Toyoshima Representative Director
In Japanese
Digitalizing Biopharma R&D Mr. HIDEKI SHIMOHIRO Managing Director
In Japanese
Prof. Dohda Takeaki 大阪大学
In Japanese
|
| Sponsor |
Oct.15(Thu.) 15 : 00 ~ 17 : 00 |
F201-202 |
|---|
| 【S-9】 Okinawa Science and Technology Promotion Center |
|---|
|
Pre-Registration required
Okinawa Initiative on Infectious Diseases and Regenerative Medicine.
|
|
Developing diagnostic test for human papillomavirus (HPV)-related cancer Dr. Taro Ikegami Assistant Professor
In Japanese
Practical use of high-performance VHH antibodies and natural bacteriophage bank for pharmaceuticals and quasi drugs. Dr. Akikazu Murakami Chief executive officer
In Japanese
A Concern on COVID-19.What we should do after COVID-19 Dr. Kobayashi Nobuyuki President & CEO
In Japanese
FDA Approval of the World's First Cotton-like Bone void filler, and Application to the Stem Cell Extraction / Culture Sheet with Bioabsorbable property. Dr. Masashi Makita Director of Laboratory
In Japanese
Regenerative medicine research at the University of the Ryukyus Prof. Yusuke Shimizu Professor
In Japanese
Development status and future development of cell culture substrate for regenerative medicine Mr. Yasutoshi Nishikawa President & CEO
In Japanese
|
| Organizer |
Oct.16(Fri.) 9 : 30 ~ 11 : 30 |
F203-204 |
|---|
| 【O-17】 Future of Cancer Genomic Medicine |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
Future of Cancer Genomic Medicine
Coordinator Mr. Mano Hiroyuki Executive Director/Director, Research Institute/Director, Center for Cancer Genomics and Advanced Therapeutics 
|
|
【Recorded Presentation】 Prof. Charles Swanton Senior Group Leader 
Early detection of cancer by a liquid biopsy Prof. Takahiro Ochiya Gene panel test reimbursed by the universal health coverage system and data accumulation in C-CAT Dr. Takashi Kohno Head
In Japanese
Precision Cancer Medicine in Japan; current status and future perspective Prof. Hiroshi Nishihara Professor
In Japanese
|
| Organizer |
Oct.16(Fri.) 12 : 00 ~ 13 : 30 |
F201-202 |
|---|
| 【O-19】 |
|---|
|
Pre-Registration required
What is needed for future biotech venture business growth?
Coordinator Prof. KUNIO ITO HITOTSUBA SHI Unibersity, Graduate School of Business Adoministration 
|
|
Mr. Tetsuya TANAKA Director
In Japanese
Mr. Daisuke TANAKA Ministry of Health, Labour and Welfare
In Japanese
Mr. Tadahisa KAGIMOTO Chairman and CEO
In Japanese
Mr. Ken TAKANASHI Executive Vice President Chief Operating Officer
In Japanese
Mr. Hiroyuki HASEGAWA Executive Officer General Manager
In Japanese
Mr. Miyuki TANABE Supporter
In Japanese
|
| Organizer |
Oct.16(Fri.) 15 : 00 ~ 16 : 30 |
F201-202 |
|---|
| 【O-20】 Post-Corona Business Model -Supply Chain/Value Chain Restructuring- |
|---|
|
Pre-Registration required
Post-Corona Business Model -Supply Chain/Value Chain Restructuring-
Coordinator Prof. TODA Yuzo President & Representative Director / Professor 
|
|
Dr. Hironobu Saito Corporate Officer, Head of Medical Affairs Division
In Japanese
Mr. koichi yamada FUJIFILM Toyama Co., Ltd.
In Japanese
Director,Economic Affair Division
In Japanese
Mr. Tetsuya Tanaka Director, Bio-Industry Division
In Japanese
TBC |
| Organizer |
Oct.16(Fri.) 15 : 30 ~ 17 : 00 |
F205-206 |
|---|
| 【O-21】 |
|---|
|
Pre-Registration required
Evolution of the Modalities in Drug DiscoveryIn view of the diversities and the changes in the drug discovery process, we start JBA Study group on Platform Technology for New Modalities in Drug Discovery. The activities are promoted with the three pillars of (1) smeWG activities, public relations, lectures, (2) enlightenment activities, and (3) activities for policies and proposals by experts, and in particular, (1) smeWG activities are positioned as the core activities. As for drug discovery modalities, we are promoting smeWG activities of next-generation antibody medicine, nucleic acid medicine, and gene & cell therapies, which are most requested by the study group members. As for the drug discovery, discussions are proceeding from three elements of therapeutic technology (modality), disease (biology), and platform (IT, production technology) from the points of view of the perspectives of technology, regulation, and business. These activities are being carried out assuming a 10-year vision with the national strategy, Bio-strategy area sixth (biomedicines), in mind. Coordinator Dr. Hitoshi Kuboniwa Corporate Advisor 
|
|
【Recorded Presentation】 Mr. EIKI Norikazu EIKI CONSULTING, LLC
In Japanese
Activity Report of Study Group on Platform Technologies for New Modalities in Drug Discovery Prof. Takeshi Wada professor
In Japanese
Gene Cell Therapy －Current and Futureー Mr. MASANOBU KIMURA Director, President of Clinical Development Division
In Japanese
|
| Sponsor |
|---|
| 【S-12】 Hitachi, Ltd. |
|---|
|
Pre-Registration required Online Seminar
Hitachi Group’s cell manufacturing solutionsPractical application of regenerative medicine and cell-based therapy is accelerating, for example, four products including CAR-T have been approved since 2019. However, there are some problems to provide a stable supply of high quality cells. Hitachi group develops various products and services, and provides solutions for industrialization of the therapy. We introduce an automated cell culture equipment for mass production, a cell analysis, sorting system for selecting high quality cells, and a cell processing facility. Coordinator Dr. Jun Otomo Chief Engineer 
|
|
Ms. Akane Hongo Regenerative Medicine Solution Group, Advanced Medical Solution Center, Analytical Systems Division, Healthcare Business Division, Smart Life Business Management Division
In Japanese
Dr. Sadao Ota Associate professor
In Japanese
Application of Ghost Cytometry in Cell Therapy Mr. Waichiro Katsuda CEO
In Japanese
Ms. Yoshimi Sugahara Front Solutions Division, Front Engineering Dept.
In Japanese
|
| Organizer |
Oct.14(Wed.) 15 : 00 ~ 16 : 30 |
F205-206 |
|---|
| 【O-4】 The forefront of research and development of regenerative medical products |
|---|
|
Pre-Registration required
The forefront of research and development of regenerative medical productsTo date, 9 regenerative medical products have been approved in Japan. New products have been approved every year since 2018, and such R&D activities are accelerating. Efforts to address the challenges toward the industrialization of regenerative medicine have become more and more important. In this session, we will invite two experts who are working on the front line of the space and have commercialized an autologous human somatic stem cell-based product and a cell-based gene therapy product, respectively. They will introduce summaries of the developments, post marketing operations, future prospects and issues regarding the two different modalities. We will expect that their experiences will catalyze active discussions with respect to the challenges of regenerative medicine. Coordinator Mr. Suzuki Kunihiko Member of the Board/Vice Chairperson 
|
|
Development of Regenerative Medical Product "Stemirac®" for the therapy of Spinal Cord Injury Mr. Yoshihiro Yoshikawa NIPRO CORPORATION
In Japanese
Development of Gene Therapy in Novartis Dr. Tohru Hirose Director, Head of Global Drug Development Division
In Japanese
|
| Organizer |
Oct.15(Thu.) 10 : 00 ~ 11 : 30 |
G301-302 |
|---|
| 【O-9】 Challenges and Future of the Supporting Industry that help the Regenerative Medicine market. |
|---|
|
Pre-Registration required
Challenges and Future of the Supporting Industry that help the Regenerative Medicine market.There are still many issues to be solved in the steady progress of regenerative medicine, and cooperation among all stakeholders is vital for further progress. In this session, following the lectures on japan and overseas efforts in regulations and quality, we invited experts from different fields and organize a panel discussion to discuss how supporting industries can support regulations and quality. Catch up on advanced cases in Japan and abroad regarding regulations and quality of regenerative medicine, and discuss actions that supporting industries should take as a guidepost for industrialization of regenerative medicine. Coordinator Mr. Kazuhiro Takekita President 
|
|
Domestic and international regulations on raw materials and manufacturing of regenerative medical products Dr. Yoji Sato Head
In Japanese
【Recorded Presentation】 Dr. Hoshiya Hidetoshi Board Director
In Japanese
Mr. Ryo Hanamura Partner
In Japanese
Legal requirements of raw materials for regenerative medicine Dr. TOSHIHIKO KAMINUMA Senior Manager
In Japanese
|
| Luncheon |
Oct.15(Thu.) 12 : 00 ~ 13 : 00 |
F201-202 |
|---|
| 【L-1】 TAKARA BIO INC. |
|---|
|
Pre-Registration required
TAKARA BIO INC. Luncheon Seminar
Coordinator Dr. Junichi Mineno TAKARA BIO INC. |
|
Dr. Toshiharu Ohba TAKARA BIO INC.
In Japanese
Mr. Masahiro Tsuji Center for Research and Development Strategy (CRDS), Japan Science and Technology Agency (JST)
In Japanese
|
| Sponsor |
Oct.15(Thu.) 13 : 30 ~ 14 : 30 |
G301-302 |
|---|
| 【S-7】 Kanagawa Prefectural Government |
|---|
|
Pre-Registration required
From Kanagawa to the World ! In order to accelerate the social implementation of regenerative medicine and cell therapy, This is the first system that we share facilities for the cell culture and processing at the Life Innovation Center finally started operation.
Coordinator Mr. Yoshiyuki Makino Kanagawa Prefectural Government 
|
|
Mr. Yoshiyuki Makino Kanagawa Prefectural Government
In Japanese
Prof. Masaya Nakamura Professor
In Japanese
Ms. Shizuka Akieda CEO
In Japanese
Mr. Ryuta Nomura Chairman of the Board
In Japanese
|
| Sponsor |
Oct.16(Fri.) 10 : 00 ~ 11 : 00 |
F205-206 |
|---|
| 【S-11】 TAKARA BIO INC. |
|---|
|
Pre-Registration required
TAKARA BIO INC. Sponsored Seminnar
|
|
Prof. Takashi Okada Director/Professor
In Japanese
Prof. Susumu Uchiyama Professor
In Japanese
|
| Organizer |
Oct.16(Fri.) 11 : 30 ~ 13 : 00 |
F205-206 |
|---|
| 【O-18】 The significance and problems of the early and conditional approval system - Is this system right or wrong? |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
The significance and problems of the early and conditional approval system - Is this system right or wrong?The early and conditional approval system is an innovative regulation that Japan was the first in the world to start. It is a suitable regulation for regenerative medicine, such as being approved early and being skilled in medical practice after commercialization, which is expected to produce even better results, but has also received criticism from overseas. In this symposium, we would like to welcome performers and panelists to include ministries, academia and pharmaceutical companies utilizing the system, and stakeholders who are objective about the system, and discuss how to position and utilize this system, and how to disseminate it overseas. Coordinator Dr. HATA KEN-ICHIRO Representative Director,Chairman 
|
|
How Japan Leads the Global Regenerative Medicine Market Mr. Colin Novick Managing Director
In Japanese
Current status and prospects of ’Conditional and Time-limited approval system’ for regenerative medicine. Mr. Sameshima Tadashi Director
In Japanese
Quality Life Cycle of Regenerative Medical Products and the Conditional Marketing Authorization System in Japan Dr. Yoji Sato Head
In Japanese
Regulatory Perspective on the conditional and time-limited authorization Dr. Daisaku Sato Associate Center Director for Regulatory Science 
|
| Organizer |
Oct.16(Fri.) 13 : 30 ~ 15 : 00 |
F203-204 |
|---|
| 【O-16】 Update in iPS Cell Research |
|---|
|
Pre-Registration required
Update in iPS Cell ResearchThis year's focus will be on whether the production and supply of iPS cell lines, which were transferred to public interest corporations from April 2020, will start smoothly and form the basis of regenerative medicine in Japan. Also, is it possible to form a new industrial base of regenerative medicine by transferring cell lines to companies? Clarify the actual situation and prospects through lectures and panel discussions. Coordinator Mr. Mitsuru Miyata CEO 
|
|
CiRA Foundation ~ Translating iPS Cells to Clinical Application Ms. Takasu Naoko Executive Director
In Japanese
|
| Sponsor |
|---|
| 【S-13】 Shonan Health Innovation Park |
|---|
|
Pre-Registration required Online Seminar
Shonan Health Innovation Park (Shonan iPark)
|
|
Session１ Toshio Fujimoto General Manager,
In Japanese
Session２ Takahiro Hagisako Head,
In Japanese
Shiro Hamanaka Manager, Pharmacist, Formulations, APIｓ＆Intermediates Marketing,
In Japanese
Session３ Toshiyuki Nomura Head,
In Japanese
Hiroyasu Mitsui Deputy General Manager, Asset Management Department
In Japanese
Session４ Keisuke Watanabe Head,
In Japanese
Shingo Soga Deputy General Manager, Business Development Office
In Japanese
Closing Remarks Jiro (MAX) Sugimoto Team Leader, Bio & Pharmaceuticals Team, Bio-Fine Chemicals Dept.
In Japanese
|
| Organizer |
Oct.15(Thu.) 9 : 30 ~ 11 : 30 |
F205-206 |
|---|
| 【O-8】 Possible future of healthcare industry |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
Possible future of healthcare industryWith the realization of a healthy and long-lived society becoming increasingly important worldwide, we will discuss the approach to healthcare as an industry and what kind of society we aim to achieve based on lectures from experts. Coordinator Dr. Katsunori Matsuoka Special Emeritus Advisor 
|
|
ICT in healthcare Prof. Ryozo Nagai President
In Japanese
【Recorded Presentation】 Dr. Murray McKinnon Global Head, 
Transformation from a pharmaceutical company to a healthcare company Dr. Ryo Shimizu Executive Officer Chief Digital Officer Vice President,Head of Digital Transformation Department
In Japanese
Ministry of Economy,Trade and Industry(METI)measures to promote the health care industry Mr. Inamura Takuma Director Healthcare Industries Division
In Japanese
|
| Sponsor |
Oct.15(Thu.) 13 : 30 ~ 14 : 30 |
F205-206 |
|---|
| 【S-6】 The National Institute of Advanced Industrial Science and Technology (AIST) |
|---|
|
Pre-Registration required
Technology development to realize high-quality, high-performance, and high-precision diagnosis and treatment of COVID-19
AIST considers COVID-19 prevention and control to be one of the most important issues and is carrying out research and development from various approaches. Coordinator Dr. Kimihiko Kameyama Deputy Director General 
|
|
Mission and strategy of our R&D in post-COVID-19 era Dr. Kimihiko Kameyama Deputy Director General
In Japanese
In silico approaches to drug repositioning for COVID-19 Dr. Takatsugu Hirokawa Chief Senior Researcher
In Japanese
Rapid real-time PCR system for COVID-19 diagnosis Dr. Hidenori Nagai Group Leader
In Japanese
NMIJ's challenges to establish metrological traceability for nucleic acid quantification Dr. Megumi Kato Group Leader
In Japanese
Smartphone-based Covid-19 IgG ELISA kit and its fully automatic diagnostic device Dr. Yusuke Fuchiwaki Senior Researcher
In Japanese
|
| Organizer |
Oct.16(Fri.) 10 : 00 ~ 11 : 30 |
F201-202 |
|---|
| 【O-15】 |
|---|
|
Pre-Registration required
Global Development of Functional Foods - Japan Food for the World -
Coordinator Prof. Teruo Miyazawa NICHe at Tohoku University 
|
|
Potential of Functional Food System Prof. Ryuichi Morishita Endowed Chair Professor
In Japanese
The current state of development of agricultural products as foods with function claims and the future of health care research through food Dr. Mari Maeda-Yamamoto Director of healthcare innovation research
In Japanese
Challenges for functional claims and global expansion of Japanese "food" Prof. Harunobu Amagase Specially Appointed Professor
In Japanese
|
| Sponsor |
|---|
| 【S-4】 Chugai Pharmaceutical Co., Ltd. |
|---|
|
Pre-Registration required Online Seminar
Digital Transformation of Chugai (English Session)
|
|
Digital Transformation of Chugai Ms. Satoko Shisai Vice President, Head of Digital & IT Supervisory Div.
In Japanese
Digital Transformation of Chugai-Innovation of drug discovery process by utilizing AI Dr. Hiroyuki Tsunoda Head of Discovery Technology Dept.
In Japanese
Digital Transformation of Chugai-Innovation of drug discovery process by utilizing Real World Data/digital bio marker Dr. Yoshito Nakanishi Head of Digital Strategy Dept.
In Japanese
|
| Sponsor |
Oct.15(Thu.) 13 : 30 ~ 15 : 00 |
G303-304 |
|---|
| 【S-8】 National Institute of Technology and Evaluation |
|---|
|
Pre-Registration required
Developing a new frontier in post COVID-19 era
|
|
National Institute of Technology and Evaluation
In Japanese
METI
In Japanese
Chitose Laboratory Corp.
In Japanese
NITE
In Japanese
|
| Organizer |
Oct.15(Thu.) 15 : 30 ~ 17 : 00 |
F205-206 |
|---|
| 【O-13】 Forefront of Digital Health |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
Forefront of Digital Health
Coordinator Dr. Ryo Shimizu Mitsubishi Tanabe Pharma Corporation 
|
|
Actions of Shionogi for Digital health innovation Mr. Yoshinori Satomi Director
In Japanese
Activities of the new business in Towa pharmaceutical Yusuke Amano Operating Officer Division Manager, Business Development Division
In Japanese
Challenges in Astellas Pharma - Rx+® Business- Mr. Yuta Watanabe Senior Vice President, Head of Rx+ Business Accelerator
In Japanese
|
| Sponsor |
|---|
| 【S-14】 GenScript Japan KK |
|---|
|
Pre-Registration required Online Seminar
How Innovative Business Models to Accelerate Cell & Gene Therapy Development
The market for cell and gene therapy is growing at an exceptional rate globally. Many vendors are making it a priority to develop and launch innovative and breakthrough cell and gene therapy products. |
|
How Innovative Business Models to Accelerate Cell & Gene Therapy Development Dr. Brian MIN CEO 
|
| Organizer |
Oct.14(Wed.) 12 : 00 ~ 13 : 30 |
G301-302 |
|---|
| 【O-1】 |
|---|
|
Pre-Registration required
Coordinator Kazuo SHIN-YA Group Leader |
|
in silico design of biosynthetic pathways with unannotated enzyme genes for chemical production Naoki Watarai Chief Executive Officer
In Japanese
Bioproduction AI management System by Using Convolutional Data Ken Kasahara Executive Officer
In Japanese
The technology for the heterologous expression and its application for the skeletal modification of middle molecular weight natural products Kazuo SHIN-YA Group Leader |
| Sponsor |
Oct.14(Wed.) 15 : 00 ~ 17 : 00 |
F201-202 |
|---|
| 【S-15】 Cross-ministerial Strategic Innovation Promotion Program(SIP)"Technologies for Smart Bio-industry and Agriculture" |
|---|
|
Pre-Registration required
Food connect a susutainable growing society. Aiming to establish a "smart food system"
To expand the bioeconomy and intensify the competitiveness of biotechnology-related industries in Japan, the program "Technologies for Smart Bio-industry and Agriculture" will contribute to the realization of growing sustainable society by establishing the innovative infrastructure through the integration of the biotechnologies and digital technologies: 1) "Diversified & Sustainable" primary production, 2)Production of biobased materials in sustainable manner, 3)"Medical care & Hearthcare" through "food", and 4)digital transformation. Today, we willl introduce "Production of biobased materials as Resource Circulation". Coordinator Wataru Mizunashi Director General, Bioeconomy Unit 
|
|
Development of Agri-biomass-based Smart Chemical Production System Jun-ichiro Hayashi Professor
In Japanese
Development of functional-design and production technologies for innovative bio-materials and products① Takahito Nakajima Team Leader
In Japanese
Development of functional-design and production technologies for innovative bio-materials and products② Yasuo Ohnishi Professor
In Japanese
Development of an Agri-biomass-based Production System of Useful Protein and Advanced Materials using Silkworm Hideki Sezutsu Leader
In Japanese
Development of Novel Technology for Bioprocess Optimization in Smart Bio-Industry Tomohiro Tamura Director General
In Japanese
|
| Organizer |
Oct.15(Thu.) 9 : 30 ~ 11 : 30 |
F201-202 |
|---|
| 【O-6】 Transition to a Carbon Neutral and Sustainable Society |
|---|
|
Pre-Registration required
Transition to a Carbon Neutral and Sustainable Society
Coordinator Prof. Yukari TAKAMURA Professor 
|
|
Mr. Tokutaro Nakai Vice-Minister
In Japanese
The role of bioeconomy to realize decarbonized society Dr. Aikawa Takanobu Renewable Energy Institute
In Japanese
Redesigning the economy and society to be sustainable and resilient through the transition to a decarbonized society Mr. Sei Kato Director, Climate Change Projects Office, Climate Change Policy Division, Global Environment Bureau
In Japanese
Moving businesses and ESG investing toward a decarbonized society Prof. Yukari Takamura Professor 
|
| Organizer |
Oct.15(Thu.) 15 : 30 ~ 17 : 00 |
F203-204 |
|---|
| 【O-12】 Towards Sustainable Consumption and Production of Plastics |
|---|
|
Pre-Registration required
Towards Sustainable Consumption and Production of Plastics
Coordinator Dr. Kuniki Kino Professor 
|
|
Corporate Alliance Initiatives for Plastic Recycling Mr. Koichi Yanagita Japan Clean Ocean Material Alliance
In Japanese
”Challenge for Innovation Across the Seven & i Group to Realize a "Prosperous and Sustainable Society"” Ms. Tsuryu Mayumi Executive officer Senior officer
In Japanese
Sustainable efforts in Suntory's packages Mr. Tatsuki Kado Senior General Manager
In Japanese
ISO standards supporting for developments of new materials and their promotions in market -bio-based content and biodegradability- Dr. Masao Kunioka National Institute of Advanced Industrial Science and Technology
In Japanese
|
| Organizer |
Oct.14(Wed.) 13 : 00 ~ 14 : 30 |
F205-206 |
|---|
| 【O-2】 |
|---|
|
Pre-Registration required
Toward the Promotion of Japan's Bioeconomy Strategy 2020 - Part 1 : About Data Connection Creating Markets - (tentative)
Data linkage is one of the most important issues in the bio-strategy, along with the bio-community and the roadmap. Coordinator Dr. Hitoshi Kuboniwa Chairman 
|
|
【Recorded Presentation】 Dr. FUJITA Tomohiro Founder and Chief executive officer of Chitose Laboratory Corp. / a member of Strategy Council in CABINET SECRETARIAT / Program-Specific Professor in Kyoto University
In Japanese
Mr. Nao Yoshizawa Attorney at Law, Patent Attorney, Vice-president, CEO representative director
In Japanese
Mr. Esaki Yoshihide
In Japanese
Mr. Noriaki Kobayashi Director of the Board, Senior Executive Officer / Project Director, Technologies for Smart Bio-industry and Agriculture Project under the Cross-ministerial Strategic Innovation Promotion Program
In Japanese
|
| Organizer |
Oct.14(Wed.) 14 : 00 ~ 16 : 30 |
G301-302 |
|---|
| 【A-1】 |
|---|
|
Pre-Registration required
Japan Bioindustry Award・Bioindustry Research Award 2020 Ceremony and Award Lecture
|
|
Japan Bioindustry Award Lecture「Therapeutic revolution in hemophilia A by creating a coagulation factor Ⅷ function-mimetic bispecific antibody」 Dr. Takehisa Kitazawa Department Manager
In Japanese
Development of highly sensitive in vivo bioluminescence imaging technolog Dr. Satoshi Iwano Researche
In Japanese
Development of new extraction and separation technologies for environmental-friendly bioindustrial production Dr. Masaki Ota Associate Professor
In Japanese
Elucidation of biological function and ecology of insecticide-degrading gut bacteria in pest insects Dr. Yoshitomo Kikuchi Senior Researcher
In Japanese
「Development of raw material production technology for high-performance biomass plastics from renewable resources using microbial fermentation」 Dr. Takeshi Kubota Senior Researcher
In Japanese
Highly sensitive nucleic acid detection method towards precise medical diagnosis of infectious diseases and cancers Dr. Ken Komiya Assistant Professor
In Japanese
「Large circular DNA amplification technology by reconstituting chromosome replication cycle」 Dr. Masayuki Su’etsugu Professor
In Japanese
Central mechanisms that modulate and transmit gustatory information Dr. Ken-ichiro Nakajima Associate Professor
In Japanese
Development of production process for useful compounds based on extensive screening of microbial enzymes Dr. Ryotaro Hara Program-Specific Associate Professor
In Japanese
Self-organization of hair follicle stem cells and its use for hair regenerative medicine Dr. Junji Fukuda Professor
In Japanese
Bio-adhesive optoelectronics for emerging photodynamic cancer therapy Dr. Toshinori Fujie Associate Professor (Lecturer)
In Japanese
|
| Organizer |
Oct.15(Thu.) 10 : 00 ~ 11 : 30 |
G303-304 |
|---|
| 【O-10】 |
|---|
|
Pre-Registration required
Promotion of the formation of the global bio comunities based on Bioeconomy Strategy 2020On the occasion after the decision of Bioeconomy Strategy2020, which refers to the formation of bio comunities, this session focuses on the policy measures to realize them and on the expectations from the frontline of businesses and R&D. Coordinator Prof. Taro HOKUGO Director for Atomic Energy, International Affairs and Biotechnology 
|
|
Implementation of the Startup Ecosystem into the Lifescience Business Dr. Koyanagi Tomoyoshi Head of TR Promotion and Education Center, Professor
In Japanese
Ms. Sachiko Mori Council for Science, Technology and Innovation, Cabinet Office, Government of Japan
In Japanese
Mr. Nao Yoshizawa Attorney at Law, Patent Attorney, Vice-president, CEO representative director
In Japanese
【Recorded Presentation】 Dr. FUJITA Tomohiro Founder and Chief executive officer of Chitose Laboratory Corp. / a member of Strategy Council in CABINET SECRETARIAT / Program-Specific Professor in Kyoto University
In Japanese
Comparative analysis of selected international bio-ecosystems – Insights for Japan Mr. Edward Willems Co-founder & Managing Director, Gold Nest Private Capital / Ginward Ltd. 
Industry expectations for the global biocommunity Ms. SAWADA TAKUKO Director and Executive Vice President and Senior Vice President of Integrated disease care Department
In Japanese
|
| Luncheon |
Oct.15(Thu.) 12 : 00 ~ 13 : 00 |
F203-204 |
|---|
| 【L-2】 Beyond Next Ventures Inc. |
|---|
|
Pre-Registration required
The growing importance of shared-labs and shared space community for biotech startups
|
|
Ms. Aki Igarashi Manager
In Japanese
Beyond Next Ventures Inc.and Biotech startups.
In Japanese
Cordinator: Takashi Nakaoka Manager 
Panelist: Toru Kanke CEO 
Panelist: Nobuyuki Fujisawa Executive Manager 
|
